SCA
GBT

Snowden Capital Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Snowden Capital Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21
Closed – – 2211
2021
Q4 		$0 Buy
+21
New +$650 ﹤0.01% 2197

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Snowden Capital Advisors's GBT Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 21 shares.

Snowden Capital Advisors first reported a position in GBT in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 21 Global Blood Therapeutics, Inc. shares in Q1 2022.
  • Snowden Capital Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Global Blood Therapeutics, Inc. position peaked at $0 in Q4 2021.
  • 204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.